Thesis
Tech + bio is the future. We fund the tools that build it.
Therapeutics get the headlines. The tools and platforms underneath decide what is possible — and when.
Where we invest
Three areas, one shared bet.
R&D tools
Instruments, reagents, and consumables that make experiments faster, cheaper, and more reproducible. Tools revenue arrives early and compounds across every therapeutic wave.
Platform technologies
Technologies with more than one shot on goal — glycoengineering, spatial biology, epigenetic regulation, point-of-care cell therapy manufacturing.
AI x Bio
Software and autonomous agents that turn biological data into decisions, from multi-omics interpretation to planning and running new methods.
How we work
Capital, coaching, and support for pre-seed founders.
Capital at the earliest moment
We write first checks into pre-seed and seed companies, often before the technology has left the founder's bench.
Operators, not spectators
Our partners have founded, scaled, and exited life science companies. We coach on product, manufacturing, and commercial strategy.
San Diego roots, global reach
Deep ties to UCSD, Salk, and the region's tools ecosystem, with a network that reaches strategics and later-stage investors.
Diverse science entrepreneurs
We look for founders in multi-omics, bioengineering, synthetic biology, and cell & gene therapies who have been overlooked by generalist funds.
What we look for
A short checklist.
- A technical insight that is hard to copy and easy to demonstrate
- A founder who has lived the problem at the bench or in the clinic
- A first product that a scientist can buy, not just admire
- A path from tools revenue to platform leverage
- Capital efficiency — milestones that fit a seed round
- A market that grows with every new therapeutic modality
Building the tools for tech + bio?
We back pre-seed and seed founders in life science tools, platform technologies, and AI x Bio.